Skip to main content
Erschienen in: Gastric Cancer 1/2021

18.07.2020 | Original Article

Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study

verfasst von: Hideomi Tomida, Toshiyuki Yoshio, Kimihiro Igarashi, Yoshinori Morita, Ichiro Oda, Takuya Inoue, Takuto Hikichi, Tetsuya Sumiyoshi, Hisashi Doyama, Yosuke Tsuji, Jun Nishikawa, Waku Hatta, Tatsuya Mikami, Mikitaka Iguchi, Kazuki Sumiyama, Katsumi Yamamoto, Kazuya Kitamura, Shiko Kuribayashi, Atsushi Yanagitani, Toshio Uraoka, Tomoyuki Yada, Kenkei Hasatani, Koichiro Kawaguchi, Tomoki Fujita, Tsutomu Nishida, Yoichi Hiasa, Mitsuhiro Fujishiro, for the FIGHT-Japan Study Group

Erschienen in: Gastric Cancer | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Delayed bleeding after gastric endoscopic submucosal dissection (ESD) in patients receiving anticoagulants remains an unpreventable adverse event. Although direct-acting oral anticoagulants (DOACs) have superior efficacy in preventing thromboembolism, their effects on the occurrence of delayed bleeding remain unclear. This study aimed to elucidate the clinical effect of DOACs on delayed bleeding after gastric ESD.

Patients and methods

We retrospectively examined 728 patients who received anticoagulants and were treated for gastric neoplasms with ESD in 25 institutions across Japan. Overall, 261 patients received DOACs, including dabigatran (92), rivaroxaban (103), apixaban (45) and edoxaban (21), whereas 467 patients were treated with warfarin.

Results

Delayed bleeding occurred in 14% of patients taking DOACs, which was not considerably different in patients receiving warfarin (18%). Delayed bleeding rate was significantly lower in patients receiving dabigatran than in those receiving warfarin and lower than that observed for other DOACs. Multivariate analysis showed that age ≥ 65, receiving multiple antithrombotic agents, resection of multiple lesions and lesion size ≥ 30 mm were independent risk factors, and that discontinuation of anticoagulants was associated with a decreased risk of bleeding. In multivariate analysis among patients taking DOACs, dabigatran therapy was associated with a significantly lower risk of delayed bleeding.

Conclusions

The effects of DOACs on delayed bleeding varied between agents, but dabigatran therapy was associated with the lowest risk of delayed bleeding. Switching oral anticoagulants to dabigatran during the perioperative period could be a reasonable option to reduce the risk of delayed bleeding after gastric ESD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRef Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRef
2.
Zurück zum Zitat Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut. 2013;62:1425–32.CrossRef Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut. 2013;62:1425–32.CrossRef
3.
Zurück zum Zitat Takizawa K, Oda I, Gotoda T, Yokoi C, Matsuda T, Saito Y, et al. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection–an analysis of risk factors. Endoscopy. 2008;40:179–83.CrossRef Takizawa K, Oda I, Gotoda T, Yokoi C, Matsuda T, Saito Y, et al. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection–an analysis of risk factors. Endoscopy. 2008;40:179–83.CrossRef
4.
Zurück zum Zitat Okada K, Yamamoto Y, Kasuga A, Omae M, Kubota M, Hirasawa T, et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc. 2011;25:98–107.CrossRef Okada K, Yamamoto Y, Kasuga A, Omae M, Kubota M, Hirasawa T, et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc. 2011;25:98–107.CrossRef
5.
Zurück zum Zitat Koh R, Hirasawa K, Yahara S, Oka H, Sugimori K, Morimoto M, et al. Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. Gastrointest Endosc. 2013;78:476–83.CrossRef Koh R, Hirasawa K, Yahara S, Oka H, Sugimori K, Morimoto M, et al. Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. Gastrointest Endosc. 2013;78:476–83.CrossRef
6.
Zurück zum Zitat Takeuchi T, Ota K, Harada S, Edogawa S, Kojima Y, Tokioka S, et al. The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. BMC Gastroenterol. 2013;13:136.CrossRef Takeuchi T, Ota K, Harada S, Edogawa S, Kojima Y, Tokioka S, et al. The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. BMC Gastroenterol. 2013;13:136.CrossRef
7.
Zurück zum Zitat Yoshio T, Nishida T, Kawai N, Yuguchi K, Yamada T, Yabuta T, et al. Gastric ESD under heparin replacement at high-risk patients of thromboembolism is technically feasible but has a high risk of delayed bleeding: Osaka University ESD Study Group. Gastroenterol Res Pract. 2013;2013:365830.CrossRef Yoshio T, Nishida T, Kawai N, Yuguchi K, Yamada T, Yabuta T, et al. Gastric ESD under heparin replacement at high-risk patients of thromboembolism is technically feasible but has a high risk of delayed bleeding: Osaka University ESD Study Group. Gastroenterol Res Pract. 2013;2013:365830.CrossRef
8.
Zurück zum Zitat Furuhata T, Kaise M, Hoteya S, Iizuka T, Yamada A, Nomura K, et al. Postoperative bleeding after gastric endoscopic submucosal dissection in patients receiving antithrombotic therapy. Gastric Cancer. 2017;20:207–14.CrossRef Furuhata T, Kaise M, Hoteya S, Iizuka T, Yamada A, Nomura K, et al. Postoperative bleeding after gastric endoscopic submucosal dissection in patients receiving antithrombotic therapy. Gastric Cancer. 2017;20:207–14.CrossRef
9.
Zurück zum Zitat Yoshio T, Tomida H, Iwasaki R, Horiuchi Y, Omae M, Ishiyama A. Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection. Dig Endosc. 2017;29:686–94.CrossRef Yoshio T, Tomida H, Iwasaki R, Horiuchi Y, Omae M, Ishiyama A. Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection. Dig Endosc. 2017;29:686–94.CrossRef
10.
Zurück zum Zitat Yoshio T, Nishida T, Hayashi Y, Iijima H, Tsujii M, Fujisaki J, et al. Clinical problems with antithrombotic therapy for endoscopic submucosal dissection for gastric neoplasms. World J Gastrointest Endosc. 2016;8:756–62.CrossRef Yoshio T, Nishida T, Hayashi Y, Iijima H, Tsujii M, Fujisaki J, et al. Clinical problems with antithrombotic therapy for endoscopic submucosal dissection for gastric neoplasms. World J Gastrointest Endosc. 2016;8:756–62.CrossRef
11.
Zurück zum Zitat Numata N, Oka S, Tanaka S, Higashiyama M, Sanomura Y, Yoshida S, et al. Clinical outcomes of endoscopic submucosal dissection for early gastric cancer in patients with chronic kidney disease. J Gastroenterol Hepatol. 2013;28:1632–7.CrossRef Numata N, Oka S, Tanaka S, Higashiyama M, Sanomura Y, Yoshida S, et al. Clinical outcomes of endoscopic submucosal dissection for early gastric cancer in patients with chronic kidney disease. J Gastroenterol Hepatol. 2013;28:1632–7.CrossRef
12.
Zurück zum Zitat Fujimoto K, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, et al. Japan Gastroenterological Endoscopy Society. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014;26:1–14.CrossRef Fujimoto K, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, et al. Japan Gastroenterological Endoscopy Society. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014;26:1–14.CrossRef
13.
Zurück zum Zitat Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Köhler C, Werth S, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35:1888–96.CrossRef Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Köhler C, Werth S, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35:1888–96.CrossRef
14.
Zurück zum Zitat Shindo Y, Matsumoto S, Miyatani H, Yoshida Y, Mashima H. Risk factors for postoperative bleeding after gastric endoscopic submucosal dissection in patients under antithrombotics. World J Gastrointest Endosc. 2016;8:349–56.CrossRef Shindo Y, Matsumoto S, Miyatani H, Yoshida Y, Mashima H. Risk factors for postoperative bleeding after gastric endoscopic submucosal dissection in patients under antithrombotics. World J Gastrointest Endosc. 2016;8:349–56.CrossRef
15.
Zurück zum Zitat Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630–9.CrossRef Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630–9.CrossRef
16.
Zurück zum Zitat Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113:625–32.CrossRef Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113:625–32.CrossRef
17.
Zurück zum Zitat Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.CrossRef Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.CrossRef
18.
Zurück zum Zitat Caldeira D, Barra M, Ferreira A, Rocha A, Augusto A, Pinto FJ, et al. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Aliment Pharmacol Ther. 2015;42:1239–49.CrossRef Caldeira D, Barra M, Ferreira A, Rocha A, Augusto A, Pinto FJ, et al. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Aliment Pharmacol Ther. 2015;42:1239–49.CrossRef
19.
Zurück zum Zitat Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.PubMedPubMedCentral Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.PubMedPubMedCentral
20.
Zurück zum Zitat Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49:2933–44.CrossRef Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49:2933–44.CrossRef
21.
Zurück zum Zitat Nagata N, Yasunaga H, Matsui H, Fushimi K, Watanabe K, Akiyama J, et al. Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis. Gut. 2018;67:1805–12.CrossRef Nagata N, Yasunaga H, Matsui H, Fushimi K, Watanabe K, Akiyama J, et al. Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis. Gut. 2018;67:1805–12.CrossRef
22.
Zurück zum Zitat Radaelli F, Fuccio L, Paggi S, Hassan C, Repici A, Rondonotti E, On behalf of Bowell Group, et al. Periendoscopic management of direct oral anticoagulants: a prospective cohort study. Gut. 2019;68:969–76.PubMed Radaelli F, Fuccio L, Paggi S, Hassan C, Repici A, Rondonotti E, On behalf of Bowell Group, et al. Periendoscopic management of direct oral anticoagulants: a prospective cohort study. Gut. 2019;68:969–76.PubMed
23.
Zurück zum Zitat Abe S, Oda I, Mori G, Nonaka S, Suzuki H, Yoshianaga S, et al. Complete endoscopic closure of a large gastric defect with endoloop and endoclips after complex endoscopic submucosal dissection. Endoscopy. 2015;47(Suppl 1):UCTN:E374-5.PubMed Abe S, Oda I, Mori G, Nonaka S, Suzuki H, Yoshianaga S, et al. Complete endoscopic closure of a large gastric defect with endoloop and endoclips after complex endoscopic submucosal dissection. Endoscopy. 2015;47(Suppl 1):UCTN:E374-5.PubMed
24.
Zurück zum Zitat Tsuji Y, Fujishiro M, Kodashima S, Ono S, Niimi K, Mochizuki S, et al. Polyglycolic acid sheets and fibrin glue decrease the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms (with video). Gastrointest Endosc. 2015;81:906–12.CrossRef Tsuji Y, Fujishiro M, Kodashima S, Ono S, Niimi K, Mochizuki S, et al. Polyglycolic acid sheets and fibrin glue decrease the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms (with video). Gastrointest Endosc. 2015;81:906–12.CrossRef
25.
Zurück zum Zitat Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost. 2014;112:918–23.CrossRef Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost. 2014;112:918–23.CrossRef
26.
Zurück zum Zitat Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99.CrossRef Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99.CrossRef
27.
Zurück zum Zitat Desai JC, Chatterjee P, Friedman K, Aisenberg J. Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants. Am J Gastroenterol Suppl. 2016;3:13–21.CrossRef Desai JC, Chatterjee P, Friedman K, Aisenberg J. Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants. Am J Gastroenterol Suppl. 2016;3:13–21.CrossRef
28.
Zurück zum Zitat Otuki S, Izumi D, Suda M, Sato A, Hasegawa Y, Yagihara N, et al. Effects of direct oral anticoagulants at the peak phase, trough phase, and after vascular injury. J Am Coll Cardiol. 2018;71:102–4.CrossRef Otuki S, Izumi D, Suda M, Sato A, Hasegawa Y, Yagihara N, et al. Effects of direct oral anticoagulants at the peak phase, trough phase, and after vascular injury. J Am Coll Cardiol. 2018;71:102–4.CrossRef
29.
Zurück zum Zitat Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or Rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662–71.CrossRef Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or Rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662–71.CrossRef
30.
Zurück zum Zitat Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627–36.CrossRef Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627–36.CrossRef
31.
Zurück zum Zitat Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168:63–9.CrossRef Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168:63–9.CrossRef
32.
Zurück zum Zitat Harada H, Suehiro S, Murakami D, Shimizu T, Nakahara R, Katsuyama Y, et al. Continuous use of low-dose warfarin for gastric endoscopic submucosal dissection: a prospective study. Endosc Int Open. 2017;5:E348–53.CrossRef Harada H, Suehiro S, Murakami D, Shimizu T, Nakahara R, Katsuyama Y, et al. Continuous use of low-dose warfarin for gastric endoscopic submucosal dissection: a prospective study. Endosc Int Open. 2017;5:E348–53.CrossRef
33.
Zurück zum Zitat Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003;61:964–8.CrossRef Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003;61:964–8.CrossRef
34.
Zurück zum Zitat Kato M, Uedo N, Hokimoto S, Ieko M, Higuchi K, Murakami K, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants (DOACs). Dig Endosc. 2018;30:433–40.CrossRef Kato M, Uedo N, Hokimoto S, Ieko M, Higuchi K, Murakami K, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants (DOACs). Dig Endosc. 2018;30:433–40.CrossRef
35.
Zurück zum Zitat Acosta RD, Abraham NS, Chandrasekhara V, Chathadi KV, Early DS, Eloubeidi MA, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83:3–16.CrossRef Acosta RD, Abraham NS, Chandrasekhara V, Chathadi KV, Early DS, Eloubeidi MA, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83:3–16.CrossRef
36.
Zurück zum Zitat Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut. 2016;65:374–89.CrossRef Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut. 2016;65:374–89.CrossRef
37.
Zurück zum Zitat Chan FKL, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut. 2018;67(3):405–17.CrossRef Chan FKL, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut. 2018;67(3):405–17.CrossRef
38.
Zurück zum Zitat Kataoka Y, Tsuji Y, Hirasawa K, Takimoto K, Wada T, Mochizuki S, et al. Endoscopic tissue shielding to prevent bleeding after endoscopic submucosal dissection: a prospective multicenter randomized controlled trial. Endoscopy. 2019;51:619–27.CrossRef Kataoka Y, Tsuji Y, Hirasawa K, Takimoto K, Wada T, Mochizuki S, et al. Endoscopic tissue shielding to prevent bleeding after endoscopic submucosal dissection: a prospective multicenter randomized controlled trial. Endoscopy. 2019;51:619–27.CrossRef
Metadaten
Titel
Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study
verfasst von
Hideomi Tomida
Toshiyuki Yoshio
Kimihiro Igarashi
Yoshinori Morita
Ichiro Oda
Takuya Inoue
Takuto Hikichi
Tetsuya Sumiyoshi
Hisashi Doyama
Yosuke Tsuji
Jun Nishikawa
Waku Hatta
Tatsuya Mikami
Mikitaka Iguchi
Kazuki Sumiyama
Katsumi Yamamoto
Kazuya Kitamura
Shiko Kuribayashi
Atsushi Yanagitani
Toshio Uraoka
Tomoyuki Yada
Kenkei Hasatani
Koichiro Kawaguchi
Tomoki Fujita
Tsutomu Nishida
Yoichi Hiasa
Mitsuhiro Fujishiro
for the FIGHT-Japan Study Group
Publikationsdatum
18.07.2020
Verlag
Springer Singapore
Erschienen in
Gastric Cancer / Ausgabe 1/2021
Print ISSN: 1436-3291
Elektronische ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-020-01105-0

Weitere Artikel der Ausgabe 1/2021

Gastric Cancer 1/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.